Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01327066 · ClinicalTrials.gov registry record · Phase 1
Electrocardiographic (ECG) Safety Study of Droxidopa at Clinical and Supratherapeutic Dose
A Phase 1 study, sponsored by Chelsea Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT01327066 is a Phase 1 study that has completed, run by Chelsea Therapeutics. The registered enrollment target is 52 participants.
The verdict
NCT01327066, a Phase 1 study, has completed, sponsored by Chelsea Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of this study is define the electrocardiographic (ECG) effects of Droxidopa at clinical (600 mg) and supratherapeutic (2000 mg) doses compared with placebo and moxifloxacin in healthy male and female subjects.
Interventions
- DRUG Placebo
- DRUG Moxifloxacin
- DRUG Droxidopa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2011-03 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01327066
The ClinicalTrials.gov registry entry for NCT01327066 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chelsea Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01327066 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01327066 about?
NCT01327066 is a clinical study titled "Electrocardiographic (ECG) Safety Study of Droxidopa at Clinical and Supratherapeutic Dose". The purpose of this study is define the electrocardiographic (ECG) effects of Droxidopa at clinical (600 mg) and supratherapeutic (2000 mg) doses compared with placebo and moxifloxacin in healthy male and female subjects.
What is the current status of trial NCT01327066?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2011-03. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01327066?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), Droxidopa (DRUG).
Who is sponsoring clinical trial NCT01327066?
This trial is sponsored by Chelsea Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.